Iron Deficiency In Pulmonary Hypertension

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions
Idiopathic Pulmonary Arterial Hypertension
Interventions
DRUG

Ferricarboxymaltose

"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."

Trial Locations (1)

Unknown

RECRUITING

VUmc, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

lead

Amsterdam UMC, location VUmc

OTHER